本ページで紹介している製品は、日本では薬機法上未承認であり、国内での販売・提供は行っておりません。
最新の製品情報はグローバルサイトをご参照ください。
The products described on this page are not approved under the Japanese regulatory framework and are not available for sale or distribution in Japan.
Please refer to the global website for the latest product information.
Quantifying allergen-specific IgG4 antibodies in serum with ImmunoCAP™ Specific IgG4 tests1 offers proper evaluation of immunological response.2 During allergen-specific immunotherapy (AIT), increased levels of allergen-specific IgG4 indicate that the immune system is responding to therapy. IgG4 has the ability to modulate the immune response to allergen and thus the potential to influence the clinical response.3
With ImmunoCAP Specific IgG4, valuable clinical information in the fields of allergic disease and immunotherapy can be obtained. Measurement of specific IgG4 antibodies have also been used in clinical studies of different allergic diseases such as asthma, rhinitis, atopic dermatitis, and gastrointestinal disorders.4,5
During immunotherapy, increased levels of specific IgG4 may indicate:
There is no common cut-off value for above normal levels of circulating specific IgG4 antibodies, as these are markers for allergen exposure, which may not be directly related to the disease and will depend on the local environment and levels of exposure.5